ArticleCurrent microbiology2025
Protein protein Interactions of NarL with NarG, SsrB, and FNR Proteins in Salmonella Typhimurium: A Comparative Analysis.
Article in Current microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Salmonella Typhimurium (STM) is the leading cause of gastroenteritis in humans and animals worldwide. Nitrate anaerobic regulator L (NarL), a global transcription factor of STM, interacts with different binding partners and thereby influences bacterial colonization and virulence under anaerobic conditions. The present study was conducted with the objective of elucidating the interactions of the NarL protein with its binding partners, such as nitrate reductase G (NarG), Secretion system regulator transcriptional activator (SsrB), and Fumarate and nitrate regulator (Fnr). Therefore, NarL, NarG, SsrB, and FNR proteins were first expressed in the prokaryotic system and the binding of NarL with NarG, SsrB, and FNR was evaluated through microtitre plate assay, dot blot, blot overlay assay, gold nanoparticle based protein binding assay, and circular dichroism spectroscopy. The NarL-NarG binding interaction was found to be significantly stronger (P < 0.05) than NarL-SsrB, followed by the NarL-FNR interaction. Binding interactions were further validated with isothermal titration calorimetry, and it was observed that the NarL-NarG interaction was exothermic with a ΔG of -16.4 kcal/mol, while the binding of NarL-SsrB was endothermic with a ΔG of 7.6 kcal/mol. However, FNR protein did not show any gain or release of free energy during interaction with NarL protein. Further, the molecular docking showed a higher binding energy score between NarL-NarG complex than NarL-SsrB and NarL-FNR protein complex. These results provide basic information that would facilitate the development of novel therapeutics against STM by targeting these specific interactions.
Indexed as
Identifiers
41222697What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.